A Phase 3, Open-Label, Long-Term Extension Study to Evaluate the Safety and Efficacy of Vosoritide in Children With Hypochondroplasia
Latest Information Update: 30 Jul 2025
At a glance
- Drugs Vosoritide (Primary)
- Indications Hypochondroplasia
- Focus Therapeutic Use
- Acronyms CANOPY-HCH-EXT
- Sponsors BioMarin Pharmaceutical
Most Recent Events
- 30 Jul 2025 New trial record